Pimavanserin, a selective serotonin (5-HT2A) antagonist/inverse agonist (20), is the only treatment approved by the US Food and Drug Administration for hallucinations and delusions associated with PD psychosis. The gene discussed is HTR2A; the disease is psychotic disorder.